{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T20:33:33Z","timestamp":1777322013492,"version":"3.51.4"},"reference-count":31,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2026,4,26]],"date-time":"2026-04-26T00:00:00Z","timestamp":1777161600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"the Commonwealth through an Australian Government Research Training Program Scholarship"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background\/Objectives: We conducted an exploratory review of patients in our institutions who had undergone a PSMA PET\/CT whilst on active surveillance, determining patient characteristics and trends. Methods: A retrospective cohort study of patients who were on active surveillance for low or favourable intermediate-risk prostate cancer and had a PSMA PET\/CT done due to the presence of risk factors was performed. Risk factors that were an indication for PSMA PET\/CT were: The presence of ISUP GG 2 disease, or ISUP GG1 disease with a PSA &gt; 10 or a PI-RADS score of 4 or 5 on their MRI. Results: We identified 45 patients who underwent PSMA PET\/CT whilst on active surveillance. Of these patients, 14 remained on active surveillance at the time of review, whilst 31 had progressed to definitive treatment. There was a significantly different distribution of PRIMARY scores between these two groups, although the average SUVMax was similar. In our practice, we found PSMA PET\/CT to be particularly useful when performing confirmatory biopsies on patients who had normal MRI scans or were unable to go for the MRI at the time of diagnosis. Conclusions: PSMA PET\/CT shows promise as a tool for active surveillance, particularly in men with risk factors for progressing to active treatment. However, our cohort was too small to draw definitive conclusions, and further research is needed.<\/jats:p>","DOI":"10.3390\/cancers18091376","type":"journal-article","created":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T19:24:51Z","timestamp":1777317891000},"page":"1376","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["PSMA PET in Active Surveillance: Initial Experiences and Future Directions"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0948-6468","authenticated-orcid":false,"given":"Jonathon","family":"Carll","sequence":"first","affiliation":[{"name":"EJ Whitten Prostate Cancer Research Centre, Epworth Healthcare, Melbourne, VIC 3052, Australia"},{"name":"Department of Urology, The Royal Melbourne Hospital, Melbourne, VIC 3052, Australia"},{"name":"Department of Surgery, University of Melbourne, Melbourne, VIC 3010, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jordan","family":"Santucci","sequence":"additional","affiliation":[{"name":"Division of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia"},{"name":"Department of Urology, Cabrini Cancer Institute, Melbourne, VIC 3144, Australia"},{"name":"Department of Urology, Queen Elizabeth II Jubilee Hospital, Brisbane, QLD 4108, Australia"},{"name":"School of Translational Medicine, Monash University, Melbourne, VIC 3800, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Whitty","sequence":"additional","affiliation":[{"name":"Department of Urology, Cabrini Cancer Institute, Melbourne, VIC 3144, Australia"},{"name":"Department of Urology, Monash Health, Melbourne, VIC 3168, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-3599-651X","authenticated-orcid":false,"given":"Jacinta","family":"Bonaddio","sequence":"additional","affiliation":[{"name":"EJ Whitten Prostate Cancer Research Centre, Epworth Healthcare, Melbourne, VIC 3052, Australia"},{"name":"Department of Urology, The Royal Melbourne Hospital, Melbourne, VIC 3052, Australia"},{"name":"Department of Surgery, University of Melbourne, Melbourne, VIC 3010, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marlon","family":"Perera","sequence":"additional","affiliation":[{"name":"Department of Surgery, University of Melbourne, Melbourne, VIC 3010, Australia"},{"name":"Division of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia"},{"name":"Department of Surgery, Austin Healthcare, Melbourne, VIC 3084, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dixon Teck Sing","family":"Woon","sequence":"additional","affiliation":[{"name":"EJ Whitten Prostate Cancer Research Centre, Epworth Healthcare, Melbourne, VIC 3052, Australia"},{"name":"Department of Surgery, University of Melbourne, Melbourne, VIC 3010, Australia"},{"name":"Department of Surgery, Austin Healthcare, Melbourne, VIC 3084, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Frydenberg","sequence":"additional","affiliation":[{"name":"Department of Urology, Cabrini Cancer Institute, Melbourne, VIC 3144, Australia"},{"name":"Department of Urology, Monash Health, Melbourne, VIC 3168, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathan","family":"Lawrentschuk","sequence":"additional","affiliation":[{"name":"EJ Whitten Prostate Cancer Research Centre, Epworth Healthcare, Melbourne, VIC 3052, Australia"},{"name":"Department of Urology, The Royal Melbourne Hospital, Melbourne, VIC 3052, Australia"},{"name":"Department of Surgery, University of Melbourne, Melbourne, VIC 3010, Australia"},{"name":"Division of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2026,4,26]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.euo.2024.07.003","article-title":"Has Active Surveillance for Prostate Cancer Become Safer? Lessons Learned from a Global Clinical Registry","volume":"8","author":"Bangma","year":"2025","journal-title":"Eur. Urol. Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1016\/j.euf.2021.06.008","article-title":"Prospective Longitudinal Health-related Quality of Life Analysis of the Finnish Arm of the PRIAS Active Surveillance Cohort: 11 Years of Follow-up","volume":"8","author":"Lokman","year":"2022","journal-title":"Eur. Urol. Focus."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.eururo.2021.12.007","article-title":"Systematic Review of Active Surveillance for Clinically Localised Prostate Cancer to Develop Recommendations Regarding Inclusion of Intermediate-risk Disease, Biopsy Characteristics at Inclusion and Monitoring, and Surveillance Repeat Biopsy Strategy","volume":"81","author":"Willemse","year":"2022","journal-title":"Eur. Urol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2795","DOI":"10.1200\/JCO.2010.33.0134","article-title":"Changes in prostate cancer grade on serial biopsy in men undergoing active surveillance","volume":"29","author":"Porten","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.urolonc.2011.06.011","article-title":"Impact of immediate TRUS rebiopsy in a patient cohort considering active surveillance for favorable risk prostate cancer","volume":"31","author":"King","year":"2013","journal-title":"Urol Oncol."},{"key":"ref_6","unstructured":"Cornford, P., Tilki, D., van den Bergh, R.C.N., Eberli, D., De Meerleer, G., De Santis, M., Gillessen, S., Henry, A.M., van Leenders, G.J.L.H., and Oldenburg, J. (2025). EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer, European Association of Urology."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/JU.0000000000002758","article-title":"Clinically Localized Prostate Cancer: AUA\/ASTRO Guideline, Part II: Principles of Active Surveillance, Principles of Surgery, and Follow-Up","volume":"208","author":"Eastham","year":"2022","journal-title":"J. Urol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1097\/JU.0000000000002757","article-title":"Clinically Localized Prostate Cancer: AUA\/ASTRO Guideline, Part I: Introduction, Risk Assessment, Staging, and Risk-Based Management","volume":"208","author":"Eastham","year":"2022","journal-title":"J. Urol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.eururo.2014.11.037","article-title":"Magnetic Resonance Imaging\u2013targeted Biopsy May Enhance the Diagnostic Accuracy of Significant Prostate Cancer Detection Compared to Standard Transrectal Ultrasound-guided Biopsy: A Systematic Review and Meta-analysis","volume":"68","author":"Schoots","year":"2015","journal-title":"Eur. Urol."},{"key":"ref_10","first-page":"Cd012663","article-title":"Prostate MRI, with or without MRI-targeted biopsy, and systematic biopsy for detecting prostate cancer","volume":"4","author":"Drost","year":"2019","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1001\/jamasurg.2024.4811","article-title":"Imaging in Diagnosis and Active Surveillance for Prostate Cancer: A Review","volume":"160","author":"Li","year":"2025","journal-title":"JAMA Surg."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/S0140-6736(20)30314-7","article-title":"Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): A prospective, randomised, multicentre study","volume":"395","author":"Hofman","year":"2020","journal-title":"Lancet"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/j.eururo.2025.03.003","article-title":"A Comprehensive Systematic Review and Meta-analysis of the Role of Prostate-specific Membrane Antigen Positron Emission Tomography for Prostate Cancer Diagnosis and Primary Staging before Definitive Treatment","volume":"87","author":"Mazzone","year":"2025","journal-title":"Eur. Urol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1111\/bju.16608","article-title":"Impact of intraprostatic PSMA maximum standardised uptake value following prostatectomy: A systematic review and meta-analysis","volume":"135","author":"Chen","year":"2025","journal-title":"BJU Int."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2955","DOI":"10.1007\/s00259-026-07806-5","article-title":"[68Ga]Ga-PSMA PET\/CT in active surveillance: From imaging to informed decision-making\u2014A \u201cWhistling Arrow\u201d perspective","volume":"53","author":"Kabasakal","year":"2026","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"3042","DOI":"10.1007\/s00259-025-07645-w","article-title":"Istanbul PSMA PET\/CT criteria (IPPC): An imaging-based approach to patient selection for active surveillance","volume":"53","author":"Kabasakal","year":"2026","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_17","first-page":"1644","article-title":"The PRIMARY Score: Using Intraprostatic 68Ga-PSMA PET\/CT Patterns to Optimize Prostate Cancer Diagnosis","volume":"63","author":"Emmett","year":"2022","journal-title":"J. Nucl. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.eururo.2021.08.002","article-title":"The Additive Diagnostic Value of Prostate-specific Membrane Antigen Positron Emission Tomography Computed Tomography to Multiparametric Magnetic Resonance Imaging Triage in the Diagnosis of Prostate Cancer (PRIMARY): A Prospective Multicentre Study","volume":"80","author":"Emmett","year":"2021","journal-title":"Eur. Urol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/bju.16214","article-title":"The CONFIRM trial protocol: The utility of prostate-specific membrane antigen positron emission tomography\/computed tomography in active surveillance for prostate cancer","volume":"133","author":"Bagguley","year":"2024","journal-title":"BJU Int."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.21037\/tau-22-708","article-title":"(68)Ga-PSMA-PET\/CT in addition to mpMRI in men undergoing biopsy during active surveillance for low- to intermediate-risk prostate cancer: Study protocol for a prospective cross-sectional study","volume":"12","author":"Gondoputro","year":"2023","journal-title":"Transl. Androl. Urol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1111\/bju.14358","article-title":"Is magnetic resonance imaging-targeted biopsy a useful addition to systematic confirmatory biopsy in men on active surveillance for low-risk prostate cancer? A systematic review and meta-analysis","volume":"122","author":"Schoots","year":"2018","journal-title":"BJU Int."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.euo.2023.05.004","article-title":"Gallium-68 Prostate-specific Membrane Antigen Positron Emission Tomography\/Computed Tomography in Active Surveillance for Prostate Cancer Trial (PASPoRT)","volume":"7","author":"Heetman","year":"2024","journal-title":"Eur. Urol. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Jain, A., Nassour, A.J., Dean, T., Patterson, I., Tarlinton, L., Kim, L., and Woo, H. (2023). Expanding the role of PSMA PET in active surveillance. BMC Urol., 23.","DOI":"10.1186\/s12894-023-01219-4"},{"key":"ref_24","first-page":"11322","article-title":"68Ga-PSMA PET\/CT evaluation in men enrolled in prostate cancer Active Surveillance","volume":"95","author":"Pepe","year":"2023","journal-title":"Arch. Ital. Urol. Androl."},{"key":"ref_25","unstructured":"MBS Online (2026, April 16). Medicare Benefits Schedule-Item 61563, Available online: https:\/\/www9.health.gov.au\/mbs\/fullDisplay.cfm?type=item&q=61563&qt=ItemID."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1097\/JU.0000000000001307","article-title":"PI-RADS\u00ae Category as a Predictor of Progression to Unfavorable Risk Prostate Cancer in Men on Active Surveillance","volume":"204","author":"Wang","year":"2020","journal-title":"J. Urol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1007\/s00259-022-06089-w","article-title":"PSMA PET\/CT: Joint EANM procedure guideline\/SNMMI procedure standard for prostate cancer imaging 2.0","volume":"50","author":"Fendler","year":"2023","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_28","unstructured":"JASP Team (JASP, 2026). JASP, Version 0.96.0; [Computer Software]."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.euo.2022.07.004","article-title":"Active Surveillance for Intermediate-risk Prostate Cancer: A Systematic Review, Meta-analysis, and Metaregression","volume":"5","author":"Baboudjian","year":"2022","journal-title":"Eur. Urol. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1111\/bju.15498","article-title":"Multiparametric magnetic resonance imaging of the prostate underestimates tumour volume of small visible lesions","volume":"129","author":"Sorce","year":"2022","journal-title":"BJU Int."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1016\/j.euo.2025.02.010","article-title":"Early Results from the CONFIRM Trial: Utility of Prostate-specific Membrane Antigen Positron Emission Tomography\/Computed Tomography in Active Surveillance for Prostate Cancer","volume":"8","author":"Liu","year":"2025","journal-title":"Eur. Urol. Onc."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/9\/1376\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T19:40:14Z","timestamp":1777318814000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/9\/1376"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,26]]},"references-count":31,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,5]]}},"alternative-id":["cancers18091376"],"URL":"https:\/\/doi.org\/10.3390\/cancers18091376","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,26]]}}}